184.60
price down icon0.53%   -0.98
 
loading
Abbvie Inc stock is traded at $184.60, with a volume of 7.80M. It is down -0.53% in the last 24 hours and up +2.65% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$185.58
Open:
$185.75
24h Volume:
7.80M
Relative Volume:
1.09
Market Cap:
$351.09B
Revenue:
$57.37B
Net Income/Loss:
$4.20B
P/E Ratio:
78.55
EPS:
2.35
Net Cash Flow:
$17.83B
1W Performance:
-6.99%
1M Performance:
+2.65%
6M Performance:
-7.47%
1Y Performance:
+15.09%
1-Day Range:
Value
$184.23
$189.77
1-Week Range:
Value
$181.64
$198.50
52-Week Range:
Value
$153.58
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
50,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2025-04-25
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.60 351.09B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
734.57 739.39B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
154.22 375.64B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
65.77 307.32B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
108.70 225.73B 53.22B 12.86B 14.85B 6.39

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
04:21 AM

AbbVie Inc. (ABBV): Among the Best Income Stocks to Invest in Now - Insider Monkey

04:21 AM
pulisher
12:15 PM

Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight - GuruFocus

12:15 PM
pulisher
May 08, 2025

Contract Research and Manufacturing Services (CRAMS) Business Report 2025: Market to Reach $211.4 Billion by 2030, Fueled by Growing Demand for Biologics and Biosimilars - GlobeNewswire Inc.

May 08, 2025
pulisher
May 08, 2025

June 27th Options Now Available For AbbVie - Nasdaq

May 08, 2025
pulisher
May 08, 2025

AbbVie Inc. (ABBV): A Bull Case Theory - MSN

May 08, 2025
pulisher
May 08, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to JoinContact The Gross Law Firm - Morningstar

May 08, 2025
pulisher
May 08, 2025

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink? - Nasdaq

May 07, 2025
pulisher
May 07, 2025

AbbVie’s Skyrizi leads pharma TV ad rankings for April - Medical Marketing and Media

May 07, 2025
pulisher
May 07, 2025

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV - TradingView

May 07, 2025
pulisher
May 07, 2025

AbbVie Files Suit Challenging Tennessee’s Contract Pharmacy Law - Bloomberg Law News

May 07, 2025
pulisher
May 07, 2025

Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com

May 07, 2025
pulisher
May 07, 2025

The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie - Yahoo

May 07, 2025
pulisher
May 07, 2025

Are Wall Street Analysts Predicting AbbVie Stock Will Climb Or Sink? - Barchart.com

May 07, 2025
pulisher
May 06, 2025

If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

AbbVie to Present at the Bank of America Securities Healthcare C - GuruFocus

May 06, 2025
pulisher
May 06, 2025

JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects? - TradingView

May 06, 2025
pulisher
May 06, 2025

AbbVie to Present at the Bank of America Securities Healthcare Conference - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

AbbVie (ABBV) Set for Gains with Medicare Policy Shift | ABBV St - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security ConcernsiShares Biotechnology ETF (NASDAQ:IBB), AbbVie (NYSE:ABBV) - Benzinga

May 06, 2025
pulisher
May 05, 2025

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.

May 05, 2025
pulisher
May 05, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth with a 6.15% Upside Potential - DirectorsTalk Interviews

May 05, 2025
pulisher
May 05, 2025

Viral Conjunctivitis Drugs Market Overall Study Report - openPR.com

May 05, 2025
pulisher
May 04, 2025

Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance

May 04, 2025
pulisher
May 03, 2025

Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV) - GuruFocus

May 03, 2025
pulisher
May 02, 2025

Fund Update: SATURNA CAPITAL CORP added 40,521 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq

May 02, 2025
pulisher
May 02, 2025

CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView

May 02, 2025
pulisher
May 02, 2025

Shareholders of Cerevel Therapeutics Holdings, Inc. Should Conta - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com

May 02, 2025
pulisher
May 01, 2025

BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - AbbVie News Center

May 01, 2025
pulisher
May 01, 2025

AbbVie shares snap seven-session gaining streak - MSN

May 01, 2025
pulisher
May 01, 2025

June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, - GlobeNewswire

May 01, 2025
pulisher
Apr 30, 2025

PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid - Law360

Apr 30, 2025
pulisher
Apr 30, 2025

Androgen Drugs Market Detailed in New Research Report By 2032 | AbbVie Inc.,Endo International plc - openPR.com

Apr 30, 2025
pulisher
Apr 30, 2025

FDA approves AbbVie’s upadacitinib for giant cell arteritis - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

AbbVie secures FDA approval for Rinvoq to treat giant cell arteritis - World Pharmaceutical Frontiers

Apr 30, 2025
pulisher
Apr 30, 2025

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis - insights.citeline.com

Apr 30, 2025
pulisher
Apr 29, 2025

AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis - Benzinga

Apr 29, 2025
pulisher
Apr 29, 2025

Why AbbVie Stock Topped the Market Today - MSN

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga

Apr 29, 2025
pulisher
Apr 29, 2025

Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie Says Rinvoq Medication Gets FDA Approval to Treat Giant Cell Arteritis - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

AbbVie (ABBV) Target Price Increased Following Strong Quarterly Results | ABBV Stock News - GuruFocus

Apr 29, 2025

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$154.22
price down icon 0.93%
drug_manufacturers_general NVO
$65.77
price up icon 1.42%
drug_manufacturers_general NVS
$108.70
price down icon 1.30%
drug_manufacturers_general MRK
$75.97
price down icon 2.16%
$265.86
price down icon 2.28%
Cap:     |  Volume (24h):